All Whitepapers

Hospitals represent a critical access point for many therapeutics. Whether a therapeutic is indicated for use exclusively in a hospital or in both inpatient and outpatient settings, hospitals are key points of drug initiation or switching. To gain access to this channel, pharma companies must understand the needs and differences of hospital systems.

MasterControl’s new e-book proves how the adoption of a data-driven and technology-supported approach to product life cycle management differentiates pharma leaders.

Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.

Virtual elements in clinical trials require extra considerations All teams involved should maintain ongoing dialogue and collaboration for success A discussion with industry leaders provides insight into such trials

An overview of marketing during the COVID-19 crisis and how to utilize various tactical solutions to successfully reach your targeted healthcare professional audiences.

LexisNexis Risk Solutions takes you inside the key considerations of making the all-important choice to partner with a data provider. Go beyond the well-polished sales pitches and understand the underlying implication of finding the right fit across 5 critical areas of business.

COVID-19 will impact demand and manifest itself in both top- and bottom-line revenue pressures. And the longer the disruption lasts, the more pressure we will see. These demand and margin pressures are at the core of the “Big Squeeze.”

- Clinical trials can be designed across a continuum of formats. - Adding decentralized elements to trials can help acquire high-quality data. - Sponsors must understand the impact across the trial landscape for success.

• Navigating global regulatory complexities requires simplification. • Technology can optimize daily activities and overall compliance. • Increasing transparency with real-time data provides more accurate insights.

In today’s evolving, value-based environment for specialty drugs, high-touch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery. Using gene therapy as a specific example, this white paper will discuss many of the high-touch services that can help enhance patient outcomes.